CClinicalTrials.gg
CompletedNCT06046976PCSDMT2Updated Oct 31, 2023

Piezosurgical vs Conventional Exodontia Surgery in Healthy and Patients With Diabetes Mellitus Type 2

An interventional study of piesosurgical extraction and conventional extraction in Diabetes Mellitus, Type 2, Surgery and Tooth Extraction Status Nos, sponsored by University of Belgrade. Completed at 1 site in Serbia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by University of Belgrade · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jun 2022, registered Dec 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study will evaluateand compare intraoperative and postoperative clinical parameters related to discomfort and wound heeling, as well as laboratory wound healing parameters after piezosurgical and conventional surgery approach during complex exodontia in healthy and patients with Diabetes Mellitus Type 2

02

Conditions studied

  • Diabetes Mellitus, Type 2
  • Surgery
  • Tooth Extraction Status Nos

Keywords

  • piesosurgery
  • exodontia
  • diabetes mellitus
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 60 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

University of Belgrade is the lead sponsor of 70 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • multiple multi-rooted teeth indicated for extraction
  • controlled DMT2

Exclusion criteria

Exclusion Criteria:

  • HbA1c >7%
  • chronic orofacial pain and infection in orofacial region
  • alcohol and tobacco consumption
  • pregnant women and nursing mothers
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Healthy

    Procedure: piesosurgical extraction · Procedure: conventional extraction

  • Experimental
    Diabetes mellitus type 2

    Procedure: piesosurgical extraction · Procedure: conventional extraction

Interventions

  • Procedurepiesosurgical extraction

    exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach

  • Procedureconventional extraction

    exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach

06

What researchers measure

Primary outcomes

  1. Duration of osteotomy

    Time frame: from the start of procedure to the end of performing osteotomy

  2. MicroRNA 21 (Mir-21) expression

    Time frame: during the first 24 hours after intervention

Secondary outcomes

  1. Duration of tooth sectioning

    Time frame: from the beginning of tooth sectioning to the end of tooth sectioning

  2. Total exodontia time

    Time frame: from the beginning of surgical procedure to the end of tooth extraction

  3. Pain intensity

    Numerical Rating Scale, measuring pain intensity ranging from 0 (no pain) to 10 (the worst pain imaginable)

    Time frame: during the first 24 hours after intervention

  4. Healing Index Score

    3 scoring levels for each of the 4 parameters considered: tissue color (1 = 100% of gingiva pink; 2 = \<50% of gingiva red, hyper- emic, movable; 3 = \>50% of gingiva red, hyperemic, movable), color and consistency of the healing tissue (1 = close grained, pink; 2 = soft, red; 3 = fragile, greenish or grayish), suppuration (1 = absent; 2 = absent but pronounced amount of plaque around socket walls; 3 = pronounced), and bleeding (1 = absent; 2 = induced by palpation; 3 = spontaneous). Thus, the scoring scale ranged from 4, corresponding to excellent healing, to 12, indicating severely impaired healing.

    Time frame: within 21 days after procedure

  5. First postoperative pain report

    time between the end of procedure and first pain experienced by the patient measured in minutes

    Time frame: within 24 hours after procedure

  6. First analgesic consumption

    time from the end of the procedure until first analgesic consumption measured in minutes

    Time frame: within 24 hours after procedure

  7. Clinical appearance of gingival tissue

    clinical appearance of the soft tissues (Visual Analogue Scale 0 to 3, according to the color and presence of edema and bleeding; ie, 0, normally pink, not edematous; 1, pink-red, slightly edematous; 2, red, edematous; and 3, red, edematous, bled easily when touched

    Time frame: within 7 days after procedure

  8. Residual Socket Volume

    the residual socket volume (RSV) is the fraction of the postextraction original cavity still open at each follow-up session (t = 3, 7, 14, and 21 days), computed as the ratio of mesiodistal (MD), bucolingual (BL) and socket depth (SD) at the follow-up session to the baseline value (t=0), measured after extraction (perfect closure corresponds to RSV = 0.00)

    Time frame: within 21 days after procedure

  9. Postextraction wound epithelization

    Epithelialization was measured as bucolingual and mesiodistal diameter of the extraction socket during the follow-up (3, 7, 14 and 21 postoperative day), expressed in millimeters

    Time frame: within 21 days after procedure

  10. Vascular Endothelial Growth Factor (VEGF) level

    detected by Enzyme-Linked Immunosorbent Essay method

    Time frame: within 24 hours after intervention

  11. Matrix Metalloproteinase 9 (MMP9) level

    detected by Enzyme-Linked Immunosorbent Essay method

    Time frame: within 24 hours after intervention

  12. Phosphatase and Tensin Homolog (PTEN) level

    detected by Enzyme-Linked Immunosorbent Essay method

    Time frame: within 24 hours after intervention

  13. Superoxide Dismutase(SOD) enzyme activity (%)

    Activity level detected by spectrophotometry using SOD Assay kit

    Time frame: within 24 hours after intervention

07

Study locations

1 site
  • University of Belgrade Faculty of Dental Medicine
    Belgrade, 11000, Serbia
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Sap

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046976
Lead sponsor
University of Belgrade
Responsible party
Bozidar Brkovic, DDS, MSc, PhD, Professor (DDS PhD, Professor, University of Belgrade) — Principal investigator
First posted
Sep 21, 2023
Start date
Jun 13, 2022
Primary completion
Oct 10, 2023
Completion
Oct 10, 2023
Last update
Oct 31, 2023

Study contacts

Milan Vucetic, DDS PHD
principal investigator · University of Belgrade Faculty of Dental Medicine
Bozidar Brkovic, DDS PhD
study director · University of Belgrade Faculty of Dental Medicine
Marija S Milic, DDS PhD
principal investigator · University of Belgrade Faculty of Dental Medicine
Jelena Roganovic, DDS PhD
principal investigator · University of Belgrade Faculty of Dental Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion